Oragenics Inc Net Income per Employee (OGEN), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Oragenics Inc   (NYSE: OGEN)
 

Oragenics Inc Net Income per Employee

OGEN's Quarterly Results, Trends, Rankings, Statistics
Oragenics Inc recorded a cumulative net loss of $-10 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 391 other companies achieving higher income per employee. While Oragenics Inc 's total ranking has deteriorated compared to the previous quarter from 3046 to 4097.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OGEN Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -3,361,136 -3,275,579 -3,280,829 -3,634,914 -3,433,674
OGEN's Total Ranking # 4097 # 3046 # 3727 # 3302 # 3129
Seq. Net Income Change - - - - -

OGEN Company Profile >> Back to OGEN Efficiency Comparisons >> Compare OGEN Net Income per Employee to its Competitors

OGEN Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 392
Healthcare Sector # 842
Overall Market # 4097

Net Income per Employee Statistics
High Average Low
$ -1,813,804 $ -4,053,444 $ -8,820,967
(Mar 31 2015)   (Mar 31 2021)




  News about Oragenics Inc Income per employee

Oragenics, Inc. Closes $1.7 Million Public Offering Amidst Financial Challenges
n



Introductionnn
On September 5, 2024, Oragenics, Inc. (NYSE American: OGEN), an innovative biotech company specializing in intranasal pharmaceuticals for treating neurological disorders, announced the successful closing of its recent public offering. This transaction raised approximately $1.7 million through the issuance of 3,078,378 shares of common stock and pre-funded warrants for an additional 5,028,206 shares, emphasizing the company’s efforts to secure capital for ongoing and future projects.
Details of the Offeringnn
The offering priced each share of common stock at $0.55, while the pre-funded warrants were priced at $0.549 each, with an exercise price of a mere $0.001 per warrant. Following the transaction, Oragenics now has a total of 8,659,071 shares of common stock outstanding and the potential to issue up to 5,028,206 additional shares through the exercise of pre-funded warrants. This capital infusion is crucial for the company as it continues to focus on developing advanced treatments for neurological conditions.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-03T12:05:26+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.